Combining AK112 with chemotherapy and Olaparib for ovarian cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2, open-label, multicohort study aims to evaluate the safety and efficacy of AK112, a bispecific monoclonal antibody targeting VEGF and PD-1, in combination with chemotherapy and/or Olaparib for patients with platinum-sensitive ovarian cancer. The study will involve female participants aged 18 and older who have histologically documented epithelial and non-mucinous platinum-sensitive ovarian cancer. Participants will receive either low or high doses of AK112 alongside standard chemotherapy and/or Olaparib, with the goal of assessing treatment outcomes based on measurable disease criteria.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Signs the written informed consent form.
2. Female participants who are at least 18 years of age on the day of signing informed consent with.
3. ECOG of 0 or 1.
4. Life expectancy ≥3 months.
5. Histologically documented epithelial and non-mucinous PSOC. PSOC was defined as radiographic progression greater than 6 months from last dose of platinum-based chemotherapy.

   Note:
   1. If breast cancer susceptibility gene (BRCA) positive participants must have received prior treatment with a poly adenosine phosphate-ribose polymerase inhibitor (PARPi).
   2. Ovarian cancer includes ovarian cancer, fallopian tube cancer and primary peritoneal cancer in this study, unless otherwise specified.
6. Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as determined by the site study team.
7. Be able to provide formalin fixed, paraffin-embedded (FFPE) tumor tissue.
8. Has adequate organ function.
9. All subjects of reproductive potential must agree to use an effective method of contraception, during and for 6 months after the last dose of study treatment.

Exclusion Criteria:

1. Other pathological types such as mucinous cancer, sex cord stromal cell tumor, etc.
2. Presence of central nervous system (CNS) metastases or carcinomatous meningitis.
3. Subjects with uncontrollable pleural, pericardial, or peritoneal effusion requiring repeated drainage.
4. Subjects with other active malignancies within 3 years prior to randomization.
5. Received systemic anti-tumor therapy within 2 weeks prior to randomization.
6. Any prior treatments targeting the mechanism of tumor immunity.
7. Major surgical , open biopsy or significant trauma within 4 weeks prior to randomization; or elective major surgical treatment required during the study.
8. Active or potentially recurrent autoimmune disease.
9. Subjects who require systemic treatment with glucocorticoid (\>10 mg/day of prednisone or equivalent glucocorticoid) or other immunosuppressive agents within 14 days prior to randomization.
10. Receiving live vaccines within 4 weeks prior to randomization.
11. Known primary or secondary immunodeficiencies, including testing positive for human immunodeficiency virus (HIV) antibodies.
12. Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
13. Known history of interstitial lung disease or non-infectious pneumonitis.
14. Serious infections requiring hospitalization.
15. Presence of active infection requiring systemic therapy.
16. Subjects with active hepatitis B and active viral hepatitis C.
17. Active or documented inflammatory bowel diseases, active diverticulitis.
18. Subjects with clinically significant cardio-cerebrovascular disease.
19. Unresolved toxicities from prior anticancer therapy.
20. History of severe hypersensitivity reactions to other mAbs.
21. Pregnant or lactating women.
22. Any condition that, in the opinion of the Investigator, may result in a risk when receiving the study drug.
23. Exclusion Criteria for combination therapy-Related: For cohort 1: Known contraindications or allergy to paclitaxel or carboplatin. For Cohorts 1-10A, Cohort 1-20A, and Cohort 2: Known contraindications or allergy to Olaparib.
24. Exclusion Criteria for AK112-Related: Known contraindications or allergy to any component of VEGF mABs or any medical conditions that affect the safety of AK112.

Where it's running

• Union Hospital Tongji Medical College Huazhong University of Science And Technology
  Wuhan, China Recruiting

Study contacts

• Study coordinator: Ting Liu, M.D.
• Email: clinicaltrials@akesobio.com
• Phone: (0760)89873999

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Rina-S with or without bevacizumab after platinum therapy for recurrent platinum-sensitive ovarian cancer

  This trial tests whether Rina-S alone or with bevacizumab works better than the investigator’s choice platinum-based chemotherapy (with or without bevacizumab) for patients with recurrent platinum-sensitive ovarian cancer.

  Recruiting at 12 sites Phase 3 Genmab · Duarte, California and 11 other locations · NCT07564141

• Rina-S plus standard care versus standard care as maintenance after second-line platinum chemotherapy for recurrent platinum-sensitive ovarian cancer

  This trial will test whether adding Rina-S to standard maintenance care helps people with recurrent platinum-sensitive ovarian cancer stay cancer-free longer after second-line platinum chemotherapy.

  Recruiting at 34 sites Phase 3 Genmab · Miami, Florida and 33 other locations · NCT07225270

• IMGN151 alone or with carboplatin, olaparib, or bevacizumab for adults with high-grade serous gynecologic cancers

  This trial tests whether IV IMGN151, given alone or with carboplatin, olaparib, or bevacizumab, can reduce disease activity and be safely tolerated in adults with high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.

  Recruiting at 21 sites Phase 2 AbbVie · Los Angeles, California and 20 other locations · NCT07024784

• Testing Rinatabart Sesutecan for advanced solid tumors

  This study is testing a new drug called Rinatabart Sesutecan to see if it can safely help people with advanced solid tumors, like certain types of ovarian and endometrial cancers.

  Recruiting at 67 sites Phase 1/2 Genmab · Phoenix, Arizona and 66 other locations · NCT05579366

• Torvutatug samrotecan with or without bevacizumab as maintenance in platinum-sensitive relapsed epithelial ovarian, fallopian tube, or primary peritoneal cancer

  This study tests torvutatug samrotecan, with or without bevacizumab, to see if it helps people with platinum-sensitive relapsed ovarian, fallopian tube, or primary peritoneal cancer stay cancer-free longer after their last platinum therapy.

  Recruiting at 3 sites Phase 3 AstraZeneca · Anchorage, Alaska and 123 other locations · NCT07816666

• Sacituzumab govitecan with bevacizumab vs standard chemotherapy for recurrent platinum-sensitive ovarian cancer after PARP inhibitor maintenance

  This phase II study tests whether sacituzumab govitecan plus bevacizumab can help people with recurrent platinum-sensitive ovarian cancer, after PARP inhibitor maintenance, more than the usual carboplatin, PLD, and bevacizumab treatment.

  Recruiting at 23 sites Phase 2 National Cancer Institute (NCI) · Fayetteville, Arkansas and 22 other locations · NCT07504588

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.